Average buy price is hidden here because at least one covered purchase quarter has no usable local mean price.
| Quarter | Action | Shares change | Est. value change | Δ Own | Shares held | Filing date |
|---|---|---|---|---|---|---|
| Q1 2026 | Reduced | −80K | – | −53.1% | 71K | May 14, 2026 |
| Q4 2025 | Reduced | −229K | – | −60.2% | 151K | Feb 12, 2026 |
| Q3 2025 | Added | +211K | – | +124.6% | 381K | Nov 13, 2025 |
| Q2 2025 | New | +169K | – | – | 169K | Aug 13, 2025 |
| Q2 2023 | New | +13K | – | – | 13K | Aug 11, 2023 |
Yes. As of Q1 2026, Jim Simons disclosed 71K shares of OBIO, worth an amount we cannot price. All figures come from SEC 13F filings for Q1 2026, the latest disclosed quarter.
Jim Simons first disclosed a OBIO position in Q2 2023; every quarterly buy and sell since is in the table above. All figures come from SEC 13F filings for Q1 2026, the latest disclosed quarter.
The quarter-by-quarter table above shows each sale and reduction Jim Simons disclosed in OBIO. All figures come from SEC 13F filings for Q1 2026, the latest disclosed quarter.
Jim Simons disclosed 71K shares of OBIO as of Q1 2026. All figures come from SEC 13F filings for Q1 2026, the latest disclosed quarter.
Jim Simons began building the OBIO position before our 13F history starts, so an exact average buy price cannot be estimated without understating it. All figures come from SEC 13F filings for Q1 2026, the latest disclosed quarter.
13F filings disclose quarter-end holdings, not trade dates or execution prices. These estimates use each covered quarter's average market price; the add average excludes the opening position and quarters without price data. All figures come from SEC 13F filings for Q1 2026, the latest disclosed quarter.
